title: Intravenous Immunoglobulin in the Treatment of Primary Immunodeficiency Diseases.
abstract: Intravenous immunoglobulin (IVIG) has been used as antibody replacement therapy in primary immunodeficiency diseases (PIDDs) for more than 50 years. Its role as a therapeutic agent has expanded over the past couple of decades as its anti-inflammatory and immune-modulatory mechanisms of action have been elucidated. It is now used "off-label" to treat other autoimmune diseases. This article focuses on the role of IVIG in the treatment of PIDDs characterized by absent or deficient antibody production. Replacement doses are given on a monthly basis in these conditions as a prophylactic measure to prevent acute and serious bacterial infections. [Pediatr Ann. 2017;46(1):e8-e12.].
authors.forename: Deirdre
authors.initials: D
authors.lastname: De Ranieri
authors.forename: Nana Sarkoah
authors.initials: NS
authors.lastname: Fenny
mesh_terms: D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use*; D007153:Immunologic Deficiency Syndromes / Q000628:therapy*
chemical_list: D016756:Immunoglobulins, Intravenous